"HIV Protease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene.
| Descriptor ID |
D016333
|
| MeSH Number(s) |
D08.811.277.656.074.500.340 D08.811.277.656.300.048.340 D12.776.964.775.375.545.750
|
| Concept/Terms |
HIV Protease- HIV Protease
- Protease, HIV
- p16 pol gene product, HIV
- p16 protease, HIV
- HIV p16 protease
- HIV Proteinase
- HTLV-III Protease
- HTLV III Protease
- Protease, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease".
This graph shows the total number of publications written about "HIV Protease" by people in this website by year, and whether "HIV Protease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Protease" by people in Profiles.
-
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct; 54(10):4253-61.
-
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother. 2009 Nov; 53(11):4869-78.
-
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1300-5.
-
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005 Aug 01; 192(3):456-65.